摘要
目的探讨可溶性肿瘤坏死因子受体检测在超声引导下经皮射频毁损(RFA)治疗原发性肝癌(HCC)的临床意义。方法采用RF2000型射频治疗仪,在B超引导下经皮RFA治疗30例HCC患者。采用双抗体夹心酶联免疫法(ELISA),检测患者RFA治疗前后血清sTNFRⅠ,sTNFRⅡ水平的改变,并检测25例HCC血清sTNFRⅠ,sTNFRⅡ与健康对照组比较。结果HCC患者RFA治疗后血清sTNFRⅠ,sTNFRⅡ水平较治疗前水平显著降低(P<0.05);HCC与对照组比较有非常显著性差异(P<0.01)。结论检测HCC患者血清sTNFRⅠ,sTNFRⅡ的水平,有助于了解患者的免疫状况,RFA治疗能有效减轻瘤负荷,改善患者机体免疫功能。
Objective To investigate the changes of serum soluble tumor necrosis factor receptors （sTNFRs） in the patients with hepatocellular carcinoma （HCC） before and after percutaneous radiofrequency ablation （RFA） treatment and evaluate their significance. Methods Thirty HCC patients were treated by electrodes inserted to the foci percutaneously under tdtrasound guidance using RF2000 generator. The levels of serum sTNFR land Ⅱ were detected before and after RFA by ELISA. Results After RFA, sTNFRⅠ and Ⅱ declined significantly （ P 〈 0.05 ）. Conclusion Examinations of sTNFRⅠ and Ⅱ are helpful to knowing the immune state. The method of RFA can improve immune function of the patients with HCC.
出处
《临床军医杂志》
CAS
2005年第4期396-397,共2页
Clinical Journal of Medical Officers
关键词
肝肿瘤
射频毁损
可溶性肿瘤坏死因子受体
liver neoplasms
radiofrequency ablation
soluble tumor necrosis factor receptor
